The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.

The Biden administration moved Friday to negotiate the prices Medicare pays for the blockbuster weight-loss drugs Ozempic and Wegovy, medications costing the massive government health program billions of dollars a year.

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday.

Novo Nordisk's Ozempic and Wegovy are among 15 drugs targeted for Medicare price negotiations in 2027. The U.S. aims to cut costs for widely used medications, under the Inflation Reduction Act. Companies must decide by February 28 if they'll join negotiations,

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face an uncertain future in the incoming Trump administration.

Biden's administration announced weight loss drugs Ozempic and Wegovy will be included on Medicare's list of medications subject to direct price negotiations.

The U.S. government named 15 drugs that will be subject to the second round of price negotiations by Medicare, including Ozempic and Wegovy, the drugs at the center of the weight-loss craze. The Biden administration said the drugs account for $41 billion in annual Medicare spending,

The two blockbusters Novo Nordisk medicines are among 15 additional drugs whose prices Medicare will be allowed to negotiate with drugmakers.